Medical Education

Medical Education Grants

Jazz Pharmaceuticals (Jazz) is committed to improving patient outcomes and providing support in compliance with local regulations.

Therapeutic Areas of Interest


  • The burden of illness and symptoms associated with Narcolepsy, including cardiometabolic comorbidities and lifelong management of disease
  • Treatment impact on Narcolepsy and associated comorbidities
  • The potential impact of excessive sodium intake on health and relevance of this risk in Narcolepsy patients (US and Canada Only)
  • Screening and diagnostic challenges of Narcolepsy
  • The impact of delayed diagnosis of Narcolepsy
Idiopathic Hypersomnia (US and Canada Only)
  • Screening, diagnosis, and management of Idiopathic Hypersomnia
  • Differentiation of Idiopathic Hypersomnia from other causes of EDS
  • Symptoms associated with Idiopathic Hypersomnia and the impact of treatment, including efficacy and safety considerations
  • The burden of illness associated with Idiopathic Hypersomnia, including comorbidities
  • Validated measures for clinical practice assessment of changes in the severity of Idiopathic Hypersomnia
  • The potential impact of excessive sodium intake on health and specific relevance of this risk in Idiopathic Hypersomnia patients

Movement Disorders
  • Screening, recognition, diagnosis, and treatment of MS Spasticity
  • MS symptoms, including spasticity, and the burden for People with Multiple Sclerosis (PwMS)
  • Deidentified data from randomized controlled trials and real-world studies for MS Spasticity treatments
  • Differentiation of MS spasticity therapies with consideration of:
    • Regulatory status
    • Treatment goal
  • The endocannabinoid system and MOA for novel treatments of spasticity in PwMS.
  • Identification, diagnosis and optimal seizure management of Lennox-Gastaut
    Syndrome (LGS), Dravet Syndrome (DS) or Tuberous Sclerosis Complex (TSC)
  • Management of patient transition from pediatric to adult practices
  • Management of patients with rare developmental and epileptic encephalopathies
    (DEEs) (e.g., LGS, DS, and TSC) beyond seizures
  • Early epilepsy treatment and improvement of long-term outcomes

Cannabinoid Science

  • Pre-clinical and clinical research on cannabinoid-based products and medicines including:
    • Systemic reviews
    • Meta analyses
    • Patient case studies
  • Evaluation of differences in evidence/data presented for cannabinoid-based products submitted for regulatory approval (including, for example FDA, EMA, MHRA, PMDA) including evaluations regarding:
    • Clinical trial evidence
    • Established and unknown risks and safety profiles associated with different cannabinoid-based products and medicines
  • Science of cannabinoids (including but not limited to):
    • Sources of cannabinoids (eg phytocannabinoids, endocannabinoids, synthetic cannabinoids)
    • Endocannabinoid system
    • Cannabis plant, phytocannabinoids and active/inactive metabolites
    • Pharmacology


Acute Myeloid Leukemia (AML)
  • The role of intensive chemotherapy in the treatment of secondary AML
  • Identification and timely, actionable diagnosis of high-risk AML subsets (e.g., AML-MRC, tAML)
  • Different technologies for the delivery of secondary AML treatments
    • Treatment of secondary AML to include:
      • Efficacy
      • Safety
      • Impact on quality of life
      • Depth of response, real world data and long-term outcomes
  • Appropriate management of secondary AML patients in the in-patient and out-patient setting
  • The AML treatment paradigm (e.g., induction, consolidation, combination therapy, maintenance therapy) and patient management
  • Clinical and economic burden of secondary AML
Endothelial Related Complications
  • Recognition, incidence, risk factors, diagnosis and early intervention of VOD/SOS including in the non-transplant setting
  • VOD/SOS diagnostic criteria, diagnostic techniques, radiologic findings and severity grading in both adult and pediatric patients
  • Pathophysiology, progressive nature and life-threatening complications of advanced VOD/SOS and other endothelial related complications
  • Efficacy, safety and mechanism of action of current therapies and patient management for the treatment of VOD/SOS
  • Clinical and economic burden of VOD/SOS and other post-transplant complications associated with endothelial cell damage
  • Efficacy and safety of current therapies and patient management for COVID-19 related ARDS and other endotheliitis
Small Cell Lung Cancer (SCLC)
  • Treatment options in second-line therapy for small cell lung cancer (SCLC)
  • Current considerations for SCLC therapies including:
    • Efficacy
    • Safety
    • Mechanism of Action
  • Patient management and safety profiles of SCLC second-line therapies
Acute Lymphoblastic Leukemia (ALL)
  • The biology of immune response, differentiation and management of asparaginase hypersensitivity reaction vs. infusion reaction and the impact and burden on safety and efficacy
  • The importance of completing treatment and potential safety or other concerns associated with current clinical mitigation strategies for hypersensitivity reactions
  • Recognition and management of asparaginase toxicities in the adult/young adult population
  • Management of pediatric and adult/young adult ALL/LBL with asparaginase (e.g., monitoring, PK, safety, clinical value)
  • Pediatric inspired protocols in the adult/young adult population
  • The efficacy and clinical benefits of new asparaginase formulation in ALL/LBL
  • Asparaginase therapies and combinations beyond ALL/LBL

View our current requests for application.

Eligible educational grant applicants include the following (not an exhaustive list):

  • Medical Schools
  • Medical Associations/Medical Societies
  • Hospitals/Medical Centers
  • Medical Education Providers

This system is currently accepting requests for medical education meetings, conferences, or symposia; medical center grand rounds lectures; fellowships; enduring medical education activities; and similar educational activities.

In Europe & International (EUR/INT) the system is also accepting requests for medical grants as allowed by local regulations.

The following grant requests are not covered by the educational grant request process: requests for funding educational activities that are promotional in nature (e.g., brand-specific promotional speaker activities); requests for funding activities related to promotion of a commercial product (e.g., commercial exhibits); and operational funding for patient advocacy organizations.

How to Apply

  • Grant requests should be submitted using the Jazz Pharmaceuticals Request Management System.
  • All grant requests should be received by Jazz in complete form at least 60 days prior to the commencement of the educational activity for consideration.
  • The system will guide applicants through the process of determining the request type and the required documents for each request.
  • Jazz Pharmaceuticals does not control or influence the content of programs or the selection of speakers, authors, or faculty planners.
  • All decisions regarding support are at the discretion of Jazz and will be communicated by email.
  • Submission of a request does not guarantee support.
  • For more information, or for questions regarding the status of a grant request, please email